Banco Bilbao Vizcaya Argentaria S.A. Common Stock (BBVA)

Cost of Revenue

€14.93B

TTM · Period ending: · EUR

BBVA logo

BBVA Cost of Revenue

Latest reported€14.93B EUR
BBVA TTM Cost of Revenue · EUR (€0.00 → €14.93B)
High-resolution chart · PNG

BBVA cost of revenue history

Trailing twelve months (TTM) · EUR. Each value covers four complete reported quarters.

Banco Bilbao Vizcaya Argentaria S.A. Common Stock Cost of Revenue — Trailing twelve months (TTM) (EUR)
Period endingCost of Revenue (EUR)
14,931,000,000
14,631,000,000
22,518,000,000
22,239,000,000
13,990,000,000
23,311,000,000
14,965,000,000
14,724,000,000
21,928,000,000
17,781,000,000
22,316,000,000
22,089,000,000
17,891,000,000
14,811,000,000
11,627,000,000
13,605,000,000
11,982,000,000
11,117,000,000
11,375,000,000
9,300,000,000
7,183,000,000
5,985,000,000
7,555,000,000
7,823,000,000
8,289,000,000
7,612,000,000
7,418,000,000
7,602,000,000
7,453,000,000
7,505,000,000
3,982,000,000
6,338,000,000
6,291,000,000
6,505,000,000
6,627,000,000
6,241,000,000
6,269,000,000
6,216,000,000
6,304,000,000
6,666,000,000
6,736,000,000
6,881,000,000
6,967,000,000
4,268,000,000
4,336,000,000
4,320,000,000
4,304,000,000
4,329,000,000
5,041,000,000
5,304,000,000
5,577,000,000
12,075,000,000
12,259,000,000
13,105,000,000
12,814,000,000
5,305,000,000
3,361,000,000
3,981,000,000
5,290,000,000
11,681,000,000
11,725,000,000
10,736,000,000
10,219,000,000
10,653,000,000
10,515,000,000
8,702,000,000
10,397,000,000
6,254,000,000
6,233,000,000
6,829,000,000
3,402,000,000
2,442,000,000
2,474,000,000
5,418,186,000
5,640,186,000
4,913,852,000
5,041,852,000
4,424,499,000
4,192,499,000
3,680,295,626
3,616,295,626
816,462,626
812,462,626
2,018,745,000
3,726,979,600
5,330,286,800
6,875,660,380
6,807,756,113
6,602,107,663
7,048,575,463
7,516,632,633
8,432,550,059
9,731,930,969
10,759,137,369
11,538,027,019
11,616,125,687
12,382,424,927
13,116,993,527
14,369,463,027
16,125,516,700
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.